Or, how do you know what you don't know? Author: Sean Colby, Data Scientist, OpenADMET Introduction At OpenADMET, we are chartered with providing data and models in support of screening molecules against anti-targets and other adverse ADMET (absorbtion, distribution, metabolism, excretion, toxicity) properties. As a motivating example, we
Additional details on the coming challenge Absorption, Distribution, Metabolism, Excretion and Toxicity–ADMET–properties can make or break preclinical and clinical development of small molecules. At OpenADMET we address the unpredictable nature of these properties through open science, generating experimental data and building predictive models of ADMET properties. A key
Small molecules continue to be the bricks and mortar of drug discovery globally, accounting for ~75% of FDA approvals over the last decade. Oral bioavailability, easily tunable properties, modulation of a wide range of mechanisms, and ease of manufacturing make small molecules highly attractive as therapeutic agents. Moreover, emerging small
Author: Pat Walters, Chief Scientist, OpenADMET Originally published on Practical Cheminformatics. Starting today, September 15, 2025, I will assume a new role as Chief Scientist at OpenADMET, an open science initiative that combines high-throughput experimentation, computation, and structural biology to enhance the understanding and prediction of absorption, distribution, metabolism, excretion,
Small molecule therapies have always been and continue to be the dominant way we treat diseases worldwide. Small molecules have unique advantages such as cost, scalability, convenience, the ability to get into every organ/cell and modulate a wide variety of targets/mechanisms – especially as compared to other modalities like